These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 7502678

  • 1. Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats.
    Mimura Y, Ogura T, Yamauchi T, Otsuka F, Oishi T, Harada K, Hashimoto M, Ota Z.
    Acta Med Okayama; 1995 Aug; 49(4):187-94. PubMed ID: 7502678
    [Abstract] [Full Text] [Related]

  • 2. Enhanced pressor response in spontaneously hypertensive rats induced by stimulation of vasopressin-V1 receptors.
    Yamauchi T, Ogura T, Oishi T, Harada K, Hashimoto M, Mimura Y, Asano N, Ota Z, Kageyama J.
    Acta Med Okayama; 1995 Feb; 49(1):53-9. PubMed ID: 7762410
    [Abstract] [Full Text] [Related]

  • 3. Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats.
    Sampey DB, Burrell LM, Widdop RE.
    Am J Physiol; 1999 Mar; 276(3):R872-9. PubMed ID: 10070150
    [Abstract] [Full Text] [Related]

  • 4. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI.
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [Abstract] [Full Text] [Related]

  • 5. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
    Furukawa Y, Takayama S, Ren LM, Sawaki S, Inoue Y, Chiba S.
    J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of V1- and V2-vasopressin (AVP) antagonists on the pressor, AVP and atrial natriuretic peptide responses to a hypertonic saline infusion in conscious anephric rats.
    Ota K, Kimura T, Inoue M, Funyu T, Shoji M, Sato K, Ohta M, Yamamoto T, Abe K.
    Eur J Endocrinol; 1995 Jul; 133(1):127-32. PubMed ID: 7627334
    [Abstract] [Full Text] [Related]

  • 9. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats.
    Intengan HD, He G, Schiffrin EL.
    Hypertension; 1998 Oct; 32(4):770-7. PubMed ID: 9774378
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differential effects of V2 vasopressin agonist and antagonists on blood pressure regulation in normotensive (WKY) and spontaneously hypertensive (SHR) rats.
    Budzikowski A, Lon S, Paczwa P, Szczepanska-Sadowska E.
    J Auton Nerv Syst; 1992 Jun 15; 39(2):87-95. PubMed ID: 1430797
    [Abstract] [Full Text] [Related]

  • 12. Effects of vasopressin V1 and V2 receptor antagonists on the development of salt-induced hypertension in Dahl rats.
    Hashimoto J, Imai Y, Minami N, Munakata M, Abe K.
    J Cardiovasc Pharmacol; 1995 Oct 15; 26(4):548-54. PubMed ID: 8569214
    [Abstract] [Full Text] [Related]

  • 13. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors.
    Feng JJ, Arendshorst WJ.
    Am J Physiol; 1996 Aug 15; 271(2 Pt 2):F304-13. PubMed ID: 8770161
    [Abstract] [Full Text] [Related]

  • 14. Role of vasopressin on cardiovascular changes during hemorrhage in conscious rats.
    Fujisawa Y, Miyatake A, Hayashida Y, Aki Y, Kimura S, Tamaki T, Abe Y.
    Am J Physiol; 1994 Nov 15; 267(5 Pt 2):H1713-8. PubMed ID: 7977803
    [Abstract] [Full Text] [Related]

  • 15. Effects of vasopressin and V1 receptors blockade on blood pressure and heart rate in spontaneously hypertensive rats.
    Stepniakowski K, Lapiński M, Noszczyk B, Januszewicz A, Szczepańska-Sadowska E.
    Pol J Pharmacol Pharm; 1991 Nov 15; 43(6):487-93. PubMed ID: 1840331
    [Abstract] [Full Text] [Related]

  • 16. Effect of nonpeptide vasopressin receptor antagonists on developing, and established DOCA-salt hypertension in rats.
    Okada H, Suzuki H, Kanno Y, Saruta T.
    Clin Exp Hypertens; 1995 Apr 15; 17(3):469-83. PubMed ID: 7613523
    [Abstract] [Full Text] [Related]

  • 17. Central V1 AVP receptors are involved in cardiovascular adaptation to hypovolemia in WKY but not in SHR.
    Budzikowski AS, Paczwa P, Szczepańska-Sadowska E.
    Am J Physiol; 1996 Sep 15; 271(3 Pt 2):H1057-64. PubMed ID: 8853341
    [Abstract] [Full Text] [Related]

  • 18. Vascular binding sites and biological activity of vasopressin in DOCA-salt hypertensive rats.
    Larivière R, St-Louis J, Schiffrin EL.
    J Hypertens; 1988 Mar 15; 6(3):211-7. PubMed ID: 3283226
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular effects of intracerebroventricular injection of vasopressin in unanaesthetized normotensive and DOCA-salt hypertensive rats.
    Berecek KH, Mah SC, Baum P, Hofbauer KG.
    J Hypertens Suppl; 1984 Dec 15; 2(3):S29-31. PubMed ID: 6599674
    [Abstract] [Full Text] [Related]

  • 20. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
    Naitoh M, Suzuki H, Murakami M, Matsumoto A, Ichihara A, Nakamoto H, Yamamura Y, Saruta T.
    Am J Physiol; 1993 Oct 15; 265(4 Pt 2):R934-42. PubMed ID: 8238468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.